With 70400.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.2 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $18.1 whereas the lowest price it dropped to was $17.5. The 52-week range on SCLX shows that it touched its highest point at $42.53 and its lowest point at $3.60 during that stretch. It currently has a 1-year price target of $630.00. Beta for the stock currently stands at 1.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SCLX was down-trending over the past week, with a drop of -5.88%, but this was up by 32.34% over a month. Three-month performance surged to 246.88% while six-month performance rose 115.01%. The stock gained 19.00% in the past year, while it has lost -54.69% so far this year. A look at the trailing 12-month EPS for SCLX yields -12.12 with Next year EPS estimates of 3.11. For the next quarter, that number is -0.91. This implies an EPS growth rate of -464.67% for this year and 188.60% for next year.
Float and Shares Shorts:
At present, 5.50 million SCLX shares are outstanding with a float of 5.46 million shares on hand for trading. On 2025-08-15, short shares totaled 0.48 million, which was 692.0 higher than short shares on 1752537600. In addition to Dr. Henry H. Ji Ph.D. as the firm’s CEO, President & Executive Chairman, Mr. Stephen Ma serves as its Senior VP, CFO & Corporate Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, SCLX reported revenue of $9896000.0 and operating income of -$20412000.0. The EBITDA in the recently reported quarter was -$27768000.0 and diluted EPS was -$7.42.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SCLX since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$21.06125 being high and -$25.41875 being low. For SCLX, this leads to a yearly average estimate of -$23.24. The surprise factor in the prior quarter was -$0.01. Based on analyst estimates, the high estimate for the next quarter is $0.07 and the low estimate is $0.07. The average estimate for the next quarter is thus $0.07.
